Advanta VXT Vascular Graft, Flixene Vascular Graft

K231972 · Atrium Medical Corporation · DSY · Mar 28, 2024 · Cardiovascular

Device Facts

• Record ID: K231972
• Device Name: Advanta VXT Vascular Graft, Flixene Vascular Graft
• Applicant: Atrium Medical Corporation
• Product Code: DSY · Cardiovascular
• Decision Date: Mar 28, 2024
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.3450
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Advanta VXT and Flixene vascular grafts are intended for use in the replacement or repair of peripheral arteries, and for use as an arteriovenous shunt for vascular access.

Device Story

Advanta VXT and Flixene vascular grafts are implantable ePTFE prostheses used for peripheral artery repair/replacement and arteriovenous dialysis access. Advanta VXT features a 2-layer ePTFE design with optional removable PTFE monofilament rings for radial support. Flixene is a 3-layer ePTFE graft designed without ring support. Devices include a Slider Graft Deployment System with polyethylene sheath and tip. Implantation occurs in a surgical suite by trained vascular surgeons. The graft serves as a conduit to restore blood flow or provide dialysis access. The device is permanent; it functions as a structural replacement for native vasculature. No electronic components, algorithms, or software are involved.

Clinical Evidence

No clinical data. Substantial equivalence is supported by non-clinical bench testing, including visual appearance, internal diameter, wall thickness, tensile strength, suture retention, kink resistance, dynamic compliance, sterility, packaging, and biocompatibility evaluations.

Technological Characteristics

Materials: expanded polytetrafluoroethylene (ePTFE), PTFE monofilament (rings), cobalt chromite blue-green Spinel ink (reference line), 303 stainless steel (deployment system), polyethylene (sheath). Configuration: 2-layer (Advanta VXT) or 3-layer (Flixene) ePTFE. Mechanical: radial/longitudinal tensile strength, suture retention, kink resistance. Sterilization: not specified. Connectivity: none. Software: none.

Indications for Use

Indicated for adult patients with peripheral vascular disease requiring open surgical repair or replacement of peripheral arteries, and patients with end stage renal disease requiring arteriovenous vascular access for dialysis.

Regulatory Classification

Identification

A vascular graft prosthesis is an implanted device intended to repair, replace, or bypass sections of native or artificial vessels, excluding coronary or cerebral vasculature, and to provide vascular access. It is commonly constructed of materials such as polyethylene terephthalate and polytetrafluoroethylene, and it may be coated with a biological coating, such as albumin or collagen, or a synthetic coating, such as silicone. The graft structure itself is not made of materials of animal origin, including human umbilical cords.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance Document for Vascular Prostheses 510(k) Submissions.”

Predicate Devices

• Advanta VXT Vascular Graft (K992960)
• Advanta VXT Vascular Graft (K992958)
• Flixene Vascular Grafts (K071923)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

March 28, 2024

Atrium Medical Corporation Hannah Scribner Regulatory Affairs Specialist II 40 Continental Blvd. Merrimack, New Hampshire 03054

Re: K231972

Trade/Device Name: Advanta VXT Vascular Graft, Flixene Vascular Graft Regulation Number: 21 CFR 870.3450 Regulation Name: Vascular graft prosthesis Regulatory Class: Class II Product Code: DSY Dated: February 27, 2024 Received: February 28, 2024

Dear Hannah Scribner:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

{1}------------------------------------------------

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

## Carmen G. Johnson -S

Carmen Gacchina Johnson, Ph.D. Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality

{2}------------------------------------------------

Center for Devices and Radiological Health Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

## Indications for Use

510(k) Number (if known) K231972/S001

Device Name

Advanta VXT Vascular Graft, Flixene Vascular Graft

#### Indications for Use (Describe)

Advanta VXT and Flixene vascular grafts are indicated for use in patients with peripheral vascular disease, where peripheral arteries must be repaired or replaced and open surgery is required. Indications for use also includes patients with end stage renal disease requiring arteriovenous vascular access for dialysis.

| Type of Use (Select one or both, as applicable) | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| <span style="font-size: 10pt;"> <b> <input checked="true" type="checkbox"/> Prescription Use (Part 21 CFR 801 Subpart D) </b> </span> | <span style="font-size: 10pt;"> <b> <input type="checkbox"/> Over-The-Counter Use (21 CFR 801 Subpart C) </b> </span> |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

# GETINGE

Atrium Medical Corporation Premarket Notification Traditional 510(k) Advanta VXT Vascular Graft Flixene Vascular Graft

Advanta VXT and Flixene Vascular Grafts 510(k) summary prepared in accordance with 21 CFR part 807.92.

### General Information

| Submitter's Name and Address | Atrium Medical Corporation<br>40 Continental Drive<br>Merrimack, NH 03054 |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Registration Number | 3011175548 |
| Contact Person | Hannah Scribner<br>Regulatory Affairs Specialist II<br>Tel: [phone]<br>Fax: [phone]<br>email: [e-mail] |
| Date Prepared | July 5, 2023 |
| Device Information | |
| Trade Name(s) | Advanta VXT Vascular Grafts<br>Flixene Vascular Grafts |
| Common/Generic Name(s) | Vascular Graft |
| Classification Name | Advanta VXT:<br>Prosthesis, Vascular Graft, Of Less Then 6mm Diameter<br>Prosthesis, Vascular Graft, Of 6mm And Greater Diameter<br>Flixene:<br>Prosthesis, Vascular Graft, Of 6mm And Greater Diameter |
| Regulation Number | 21 CFR 870.3450 |
| Product Codes | Advanta VXT:<br>DSY (Prosthesis, Vascular Graft, of 6MM and Greater<br>Diameter)<br>DYF (Prosthesis, Vascular Graft, of less than 6MM<br>Diameter)<br>Flixene:<br>DSY (Prosthesis, Vascular Graft, of 6MM and Greater<br>Diameter) |
| Device Class | The Advanta VXT and Flixene Vascular Grafts are classified<br>as Class II devices according to 21 CFR 870.3450 |

{5}------------------------------------------------

Atrium Medical Corporation Premarket Notification Traditional 510(k) Advanta VXT Vascular Graft Flixene Vascular Graft

#### Predicate Device Information:

The predicate devices are Atrium Medical Corporation's, Advanta VXT Vascular Graft (K992960: October 01, 1999). Advanta VXT Vascular Graft (K992958: October 01, 1999) and Flixene Vascular Grafts (K071923: August 14, 2007).

Advanta VXT is represented by two (2) predicate 510(k)'s in this submission as K992958 (Product Code: DYF) is specific to grafts 6mm in diameter or less and K992960 (Product Code: DSY) is specific to grafts 6mm in diameter or greater.

The Advanta VXT and Flixene Vascular Grafts, subject of this submission, are substantially equivalent in function and intended use as the predicate devices.

### Subject Device Description:

Atrium ePTFE vascular grafts are offered in a variety of designs; (including Advanta VXT and Flixene). They are made primarily of expanded polytetrafluoroethylene (ePTFE), and are available in a wide variety of configurations:

- . "Rings" (also referred to as "helix") for added radial support (made from a PTFE monofilament coil)
- . The Slider Graft Deployment System consisting of a pre-attached tip(s) with a clear flexible sheath (polyethylene)
- . Tapered end
- . Thin or standard wall thickness

The Advanta VXT graft is a 2-layer graft employing a single-layer ePTFE graft, which is then wrapped with an additional layer of ePTFE for increased support. The rings available on some Advanta VXT grafts are bonded to the exterior surface of the graft. By following the prescribed procedure, the rings can be removed incrementally as needed. The Flixene vascular graft is a 3layer graft comprised of ePTFE. This graft was designed with an additional layer of ePTFE. As a result of its design, ring support is not necessary. Implantable portion of graft is comprised of polytetrafluoroethylene (PTFE) with no more than 0.1% cobalt chromite blue-green Spinel ink on

{6}------------------------------------------------

Atrium Medical Corporation Premarket Notification Traditional 510(k) Advanta VXT Vascular Graft Flixene Vascular Graft

surface of the graft, which is used as a reference line. Additional materials in transient contact during placement of the graft include 303 stainless steel and polyethylene, which represents the graft deployment system and transfer sleeve.

#### Subject Device Intended Use:

Advanta VXT and Flixene vascular grafts are intended for use in the replacement or repair of peripheral arteries, and for use as an arteriovenous shunt for vascular access.

#### Subject Device Indication for Use:

Advanta VXT and Flixene vascular grafts are indicated for use in patients with peripheral vascular disease, where peripheral arteries must be repaired or replaced and open surgery is required. Indications for use also includes patients with end stage renal disease requiring arteriovenous vascular access for dialysis.

### Intended Use Environment, User/Operator, Patient population, and Intended Use

The following elements are substantially equivalent between the predicate and subject devices.

| | Predicate Devices<br>Advanta VXT (K992960 and K992958)<br>Flixene (K071923) | Subject Devices<br>Advanta VXT<br>Flixene |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Intended Use<br>Environment | Surgical Suite | Same as Predicate |
| Intended User/Operator | They are intended to be implanted by surgeons<br>trained in the theoretical, technical and clinical<br>aspects of vascular reconstruction, bypass and<br>creation of arteriovenous vascular access.<br>Other potential users include dialysis-related<br>nursing staff and clinicians trained in generic<br>vascular access use. | Same as Predicate |
| Intended Patient<br>Population | Advanta VXT and Flixene vascular grafts are<br>intended for use in adult patients. | Same as Predicate |
| Intended Use | Advanta VXT and Flixene vascular grafts are<br>intended for use in the replacement or repair of<br>peripheral arteries, and for use as an<br>arteriovenous shunt for vascular access. | Same as Predicate |

Intended Use Environment, User/Operator, Patient population, and Intended Use Table 1

{7}------------------------------------------------

# GETI

Atrium Medical Corporation Premarket Notification Traditional 510(k) Advanta VXT Vascular Graft Flixene Vascular Graft

Image /page/7/Picture/2 description: The image shows a close-up of a medical device, possibly a catheter or similar instrument. The device has a white, flexible tube with dashed lines along its length, and the word "atrium" is printed on the tube. The tube is connected to a metallic connector with a screw-like tip.

Vascular Graft Example Figure 1

### Technological characteristics:

Atrium's Advanta VXT and Flixene Vascular grafts, subject of this submission, are technologically different from the predicate devices (K071923, K992960 and K992958) as there are differences in the materials of construction.

Atrium's Advanta VXT and Flixene Vascular grafts, subject of this submission, have the same Device Configuration Options as the predicate devices (K071923, K992960 and K992958).

### Major Materials of Construction

The Advanta VXT and Flixene Vascular Grafts, subject of this submission, have different materials of construction then the predicate devices.

### Non-clinical Tests

Advanta VXT and Flixene Vascular Grafts comply with the voluntary standards. Atrium Medical's development process required that the following activities be completed during the development of the current configuration of the Advanta VXT and Flixene Vascular Grafts:

| Non-Clinical Bench Testing | |
|----------------------------|----------------------|
| Visual Appearance | Water Entry Pressure |
| Relaxed Internal Diameter | Dynamic Compliance |

{8}------------------------------------------------

# GETI

Atrium Medical Corporation Premarket Notification Traditional 510(k) Advanta VXT Vascular Graft Flixene Vascular Graft

| Non-Clinical Bench Testing | |
|----------------------------------------------|----------------------------------------|
| Pressurized Internal Diameter | Kink Resistance |
| Wall Thickness | Graft Deployment System Pull Strength |
| Useable Length | Helix Peel Strength (Advanta VXT only) |
| Graft Surface Architecture | Wrap Properties |
| Suture Retention Strength | Material Composition and Construction |
| Radial Tensile Strength | Modification of Length and/or End |
| Longitudinal Tensile Strength | Print Legibility |
| Strength after Repeated Puncture | Shelf-life Validation |
| Other Non-Clinical Testing | |
| Sterility Validation | MR Compatibility |
| Packaging Validation | Biocompatibility Evaluation |
| Chemical Characterization Analytical Testing | Toxicological Risk Assessment |

### Clinical Tests

There were no clinical studies of the modified device.

### Conclusion

The Advanta VXT and Flixene Vascular Grafts are substantially equivalent to the predicate devices in the fundamental scientific technology of the device. The design verification and validation testing established that the Advanta VXT and Flixene Vascular Grafts are substantially equivalent to the predicate devices.

Based upon the information submitted in this Traditional 510(k) premarket notification, Advanta VXT and Flixene Vascular Grafts subject of this submission are substantially equivalent to the predicate devices Advanta VXT Vascular Graft (K992960 and K992958) and Flixene Vascular Grafts (K071923).